Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced it was ...
Designation highlights significant unmet medical needAUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ...
The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...
-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...
Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...
Animate Biosciences today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that ...
When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...
In patients with cystic fibrosis, CMTX-101, an immune-enabling antibody therapy, lowered four inflammatory biomarkers and ...
In idiopathic pulmonary fibrosis, 12 months of pulmonary rehabilitation increased cerebral oxygenation during exercise, ...
Please provide your email address to receive an email when new articles are posted on . Researchers captured exercise capacity measures during the first week of pulmonary rehabilitation to the session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback